EUROPEAN MCL NETWORK - European Mantle Cell Lymphoma Network: Translational determination of molecular prognostic factors and pharmacogenomics in a European interdisciplinary collaboration (FP6-LIFESCIHEALTH) (2004-07-01 - 2007-06-30) (»add to infobox)

Wolfgang HIDDEMANN, Philip K, Christiane POTT, Niels Smedegaard ANDERSEN, Gilles SALLES, Jose Angel MARTINEZ-CLIMENT, Elizabeth MACINTYRE, Jacobus Johannes Maria VAN DONGEN, Thomas MEITINGER, Vincent RIBRAG, Elias CAMPO, German OTT, Brigitte SCHLEGELBERGER, Stephan STILGENBAUER, Johannes H. J. M. VAN KRIEKEN, Marek TRNENY, Jan WALEWSKI

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE212 - München, Kreisfreie Stadt) (Germany), ACADEMISCH ZIEKENHUIS GRONINGEN (NL113 - Overig Groningen) (Netherlands), UNIVERSITY HOSPITAL SCHLESWIG-HOLSTEIN/CAMPUS KIEL (DEF02 - Kiel, Kreisfreie Stadt) (Germany), COPENHAGEN UNIVERSITY HOSPITAL (DK001 - København og Frederiksberg kommuner) (Denmark), UNIVERSITE CLAUDE BERNARD LYON 1 (FR716 - Rhône) (France), FUNDACION DE INVESTIGACION DEL HOSPITAL CLINICO UNIVERSITARIO OF VALENCIA (ES523 - Valencia / València) (Spain), ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR101 - Paris) (France), ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (NL335 - Groot-Rijnmond) (Netherlands), GSF - FORSCHUNGSZENTRUM FUER UMWELT UND GESUNDHEIT GMBH (DE21 - Oberbayern) (Germany), INSTITUT GUSTAVE ROUSSY (FR107 - Val-de-Marne) (France), HOSPITAL CLINIC I PROVINCIAL DE BARCELONA (ES511 - Barcelona) (Spain), BAYERISCHE JULIUS-MAXIMILIANS UNIVERSITAET WUERZBURG (DE263 - Würzburg, Kreisfreie Stadt) (Germany), MEDIZINISCHE HOCHSCHULE HANNOVER (DE929 - Region Hannover) (Germany), UNIVERSITY OF ULM (DE144 - Ulm, Stadtkreis) (Germany), RADBOUD UNIVERSITEIT NIJMEGEN - STICHTING KATHOLIEKE UNIVERSITEIT (NL223 - Arnhem/Nijmegen) (Netherlands), UNIVERZITA KARLOVA V PRAZE (CZ010 - Hlavni mesto Praha) (Czech Republic), MARIA SKLODOWSKA-CURIE MEMORIAL CANCER CENTER (PL127 - Miasto Warszawa) (Poland)

Mantle cell lymphoma (MCL) is a distinct, clinically very aggressive subentity of malignant lymphoma with a median survival of 3 years. However, a small subset of patients represents long-term survivors. So far, the discriminative power of different prognostic parameters has been limited. Thus, a better understanding of the underlying molecular mechanisms is eagerly warranted. In the last few years, European-wide MCL networks of clinicians (European MCL Intergroup Working Party), pathologists (European MCL Pathology Panel) and basic researchers (European MCL Research Network) have been established to investigate the clinical as well as molecular aspects of malignant transformation and progression in MCL. Especially, strict diagnostic histomorphological criteria have been defined; in a prospective randomized study, an intensive consolidation with high dose radiochemotherapy and subsequent autologous stem cell transplantation resulted in superior progression-free and overall survival rates; and most interestingly, proliferation indices have been identified as the most important prognostic factors in MCL superior to clinical parameters (IPI). Based on these extensive prerequisites and the recent development of innovative molecular techniques (matrix CGH, RNA array chips, RQ-PCR, proteomics), we propose a global approach to investigate innovative treatment options of MCL and evaluate new predictive (pharmaco- genomics, minimal residual disease) and prognostic molecular markers (genomic alterations, RNA/proteome profiles) in such controlled studies. This translational approach of the European MCL Network will not only lead to more individualized therapeutic strategies based on a molecular risk profile but will also finally elucidate the way to future molecular targeted treatment options in a subtype of malignant lymphoma with an otherwise dismal clinical outcome.

PERSONS (17/17)

RELATED NAVIGATION AREA(S) (2/2)